411 related articles for article (PubMed ID: 31107146)
1. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
[No Abstract] [Full Text] [Related]
2. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
[TBL] [Abstract][Full Text] [Related]
3. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
4. Is There an Association Between Use of Amoxicillin-Clavulanate and Resistance to Third-Generation Cephalosporins in Klebsiella pneumoniae and Escherichia coli at the Hospital Level?
Marquet A; Vibet MA; Caillon J; Javaudin F; Chapelet G; Montassier E; Batard E
Microb Drug Resist; 2018 Sep; 24(7):987-994. PubMed ID: 29489447
[TBL] [Abstract][Full Text] [Related]
5. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
6. Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Thelen H; Dilworth TJ; Mercier RC
Chemotherapy; 2022; 67(4):261-268. PubMed ID: 36417841
[TBL] [Abstract][Full Text] [Related]
7. Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
Al-Tamimi M; Albalawi H; Shalabi M; Abu-Raideh J; Khasawneh AI; Alhaj F
Ann Clin Microbiol Antimicrob; 2022 May; 21(1):20. PubMed ID: 35599329
[TBL] [Abstract][Full Text] [Related]
8. [Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase producing urinary isolates of Escherichia coli in outpatients].
Marković T; Jeinić L; Smitran A; Petković M
Srp Arh Celok Lek; 2013; 141(11-12):775-9. PubMed ID: 24502096
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
10. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
12. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
13. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
[TBL] [Abstract][Full Text] [Related]
14. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
15. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.
Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF
World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
17. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
Stewart AG; Bauer MJ; Butkiewicz D; Hinton A; Henderson A; Harris PNA; Paterson DL
Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
[TBL] [Abstract][Full Text] [Related]
19. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
[No Abstract] [Full Text] [Related]
20. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
